Efficacy of Ashtangavaleha on bronchial asthma

Phase 2

Completed

• Conditions: Health Condition 1: J453- Mild persistent asthmaHealth Condition 2: null- Tamaka Shwasa

• Registration Number: CTRI/2016/06/007010
• Lead Sponsor: Institute for Post Graduate Teaching and Research in Ayurveda

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Study Completion: 2018-01-18
• Last Update Posted: 24 November 2021

Recruitment & Eligibility

• Status: Completed
• Sex: Not specified
• Target Recruitment: 105

Inclusion Criteria

Both the sexes having age between 16 years to 60 years

Mild persistent cases of Bronchial Asthma with daytime symptoms 3-6/week and nocturnal symptoms with 3-4/month

Moderate persistence cases with daytime symptoms daily and nocturnal symptoms with one or more than one week but not more than 2 week

Exclusion Criteria

Known patients of diabetes

Dyspnoea resulting from cardiac origin and anaemia

Age above 60 years and below 16 years

Patients suffering from tuberculosis, malignancy and other chronic debilitating diseases, HIV positive cases

Pregnant and lactating mothers

Patients who depend on regular use of inhalers

Patients suffering with other types of Shwasa, i.e. Maha, Urdha, Chhinna Shwasa

Study & Design

• Study Type: Interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
It is expected that the trial drugs will exert a significant action on Signs and Symptoms of Tamaka Shwasa. Improvement in AEC and other haematological <br/ ><br>(TLC, DLC, Hb, AEC), Peak Expiratory Flow Rate and Breath Holding Time.Timepoint: Improvement in signs and symptoms, BHT and PEFR will be assessed before and after treatment (28 days of drug administration)

Secondary Outcome Measures

Name	Time	Method
By providing better effect on Tamaka Shwasa, the drug will effect psychosomatic level of the enrolled patients, enhance quality of life and will contribute in reducing disability adjusted life years. <br/ ><br>Overall improvement in the disease condition, <br/ ><br>Quality of Life of the diseased. <br/ ><br>Based on the observations, the trial drug may be <br/ ><br>recommended to be added into the Essential Drugs List of Ministry of AYUSH, New DelhiTimepoint: 18 Months of Trial